NCT05687721View on ClinicalTrials.gov

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 2, 2025

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions
Advanced Urothelial Carcinoma
Interventions
DRUG

copanlisib

intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles

DRUG

Avelumab

800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles

Trial Locations (1)

02130-4817

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

VA Office of Research and Development

FED

NCT05687721 - Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Biotech Hunter | Biotech Hunter